↓ Skip to main content

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)

Overview of attention for article published in Journal of Neuroinflammation, January 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
8 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
Published in
Journal of Neuroinflammation, January 2016
DOI 10.1186/s12974-016-0648-x
Pubmed ID
Authors

Vaknin-Dembinsky, Adi, Charbit, Hanna, Brill, Livnat, Abramsky, Oded, Gur-Wahnon, Devorah, Ben-Dov, Iddo Z, Lavon, Iris, Adi Vaknin-Dembinsky, Hanna Charbit, Livnat Brill, Oded Abramsky, Devorah Gur-Wahnon, Iddo Z. Ben-Dov, Iris Lavon

Abstract

Neuromyelitis optica (NMO) is a chronic autoimmune disease of the central nervous system (CNS). The main immunological feature of the disease is the presence of autoantibodies to Aquaporin 4 (AQP4+), identified in about 82 % of cases. Currently, there are no reliable biomarkers for monitoring treatment response in patients with NMO. In an effort to identify biomarkers, we analyzed microRNAs (miRNAs) in the blood of rituximab-treated NMO patients before and after therapy. Total RNA extracted from whole blood of nine rituximab-responsive NMO patients before and 6 months following treatment was subjected to small RNAseq analysis. The study included an additional group of seven untreated AQP4+ seropositive NMO patients and 15 healthy controls (HCs). Fourteen miRNAs were up regulated and 32 were downregulated significantly in the blood of NMO patients following effective therapy with rituximab (all p < 0.05). Furthermore, we show that expression of 17 miRNAs was significantly higher and of 25 miRNAs was significantly lower in untreated NMO patients compared with HCs (all p < 0.05). Following rituximab treatment, the expression levels of 10 of the 17 miRNAs that show increased expression in NMO reverted to the levels seen in HCs. Six of these "normalized" miRNAs are known as brain-specific/enriched miRNAs. Specific miRNA signatures in whole blood of patients with NMO might serve as biomarkers for therapy response. Furthermore, monitoring the levels of brain-specific/enriched miRNAs in the blood might reflect the degree of disease activity in the CNS of inflammatory demyelinating disorders.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 17%
Student > Ph. D. Student 4 11%
Student > Postgraduate 4 11%
Student > Doctoral Student 3 9%
Other 3 9%
Other 9 26%
Unknown 6 17%
Readers by discipline Count As %
Medicine and Dentistry 14 40%
Neuroscience 5 14%
Agricultural and Biological Sciences 3 9%
Biochemistry, Genetics and Molecular Biology 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 3 9%
Unknown 7 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2016.
All research outputs
#6,409,497
of 12,378,687 outputs
Outputs from Journal of Neuroinflammation
#537
of 1,418 outputs
Outputs of similar age
#99,383
of 266,465 outputs
Outputs of similar age from Journal of Neuroinflammation
#29
of 51 outputs
Altmetric has tracked 12,378,687 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,418 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.